Hostname: page-component-cb9f654ff-nr592 Total loading time: 0 Render date: 2025-08-23T16:01:17.921Z Has data issue: false hasContentIssue false
  • English
  • Français

Transcutaneous vagal nerve stimulation for the treatment of trauma- and stressor-related disorders: systematic review of randomised controlled studies

Published online by Cambridge University Press:  01 August 2025

Tarek Benzouak Open the ORCID record for Tarek Benzouak [Opens in a new window] ,
Chad Danyluck Open the ORCID record for Chad Danyluck [Opens in a new window] ,
Sasha Gunpat Open the ORCID record for Sasha Gunpat [Opens in a new window] ,
Steve E. Amougou Open the ORCID record for Steve E. Amougou [Opens in a new window] ,
Rami A. Hamoudeh Open the ORCID record for Rami A. Hamoudeh [Opens in a new window] ,
Michael A. Prudencio-Brunello Open the ORCID record for Michael A. Prudencio-Brunello [Opens in a new window] ,
Jude Nachabe Open the ORCID record for Jude Nachabe [Opens in a new window] ,
Febin Edwin ,
Steve Kisely Open the ORCID record for Steve Kisely [Opens in a new window]  and
Sanjay Rao Open the ORCID record for Sanjay Rao [Opens in a new window]
Tarek Benzouak
Affiliation:
Faculty of Medicine, McGill University, Quebec, Canada Department of Psychiatry, University of Ottawa, Ontario, Canada Department of Psychology, Carleton University, Ontario, Canada
Chad Danyluck
Affiliation:
Department of Psychology, Carleton University, Ontario, Canada
Sasha Gunpat
Affiliation:
Department of Psychology, Concordia University, Quebec, Canada
Steve E. Amougou
Affiliation:
Faculty of Medicine, McGill University, Quebec, Canada
Rami A. Hamoudeh
Affiliation:
Faculty of Medicine, McGill University, Quebec, Canada
Michael A. Prudencio-Brunello
Affiliation:
Faculty of Medicine, McGill University, Quebec, Canada
Jude Nachabe
Affiliation:
Department of Psychology, Concordia University, Quebec, Canada
Febin Edwin
Affiliation:
Department of Psychiatry, University of Ottawa, Ontario, Canada
Steve Kisely
Affiliation:
Departments of Psychiatry, Community Health & Epidemiology, Dalhousie University, Nova Scotia, Canada Department of Psychiatry, University of Queensland, Queensland, Australia
Sanjay Rao*
Affiliation:
Department of Psychiatry, University of Ottawa, Ontario, Canada
*
Correspondence: Sanjay Rao. Email: sra4@uottawa.ca
Rights & Permissions [Opens in a new window]

Abstract

Background

Vagal nerve stimulation (VNS) has recently emerged as a prospective therapeutic approach for addressing trauma- and stressor-related disorders (TSRDs).

Aims

We assessed findings from randomised controlled trials for the safety and efficacy of VNS as a viable treatment for TSRDs.

Method

We systematically searched Medline, Embase, PsycINFO, CINAHL, Web of Science, Cochrane Central databases, trial registries, preprint servers and Google Scholar from inception to December 2023. Rayyan software was used for screening procedures. Two reviewers independently completed data extraction based on the inclusion criteria.

Results

We synthesised data by using a narrative approach. A total of 322 abstracts were identified and assessed, and seven studies were included in the review. Based on evidence synthesis, the present state of VNS as a treatment intervention for TSRDs, namely post-traumatic stress disorder (PTSD), is limited and does not meet clinical expectations. The overall certainty of evidence was very low. However, evidence shows that VNS may alter and reduce specific aspects associated with PTSD phenomenology, including the reduction of anger responses and the attenuation of hyperarousal during psychological interventions.

Conclusions

Although preliminary analyses provide evidence that transcutaneous VNS temporarily increases parasympathetic activity under specific conditions, these effects appear to be short-lasting, and the impact of repeated administration on long-term autonomic function remains unknown. Future randomised control trials should evaluate the therapeutic efficacy of VNS for treating TSRDs.

Keywords

Trauma and stressor related disorderspost traumatic stress disordervagal nerve stimulationsystematic review

Information

Type
Review
Information
BJPsych Open , Volume 11 , Issue 5 , September 2025 , e165
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Trauma- and stressor-related disorders (TSRDs) share a common aetiological pathway and are characterised by exposure to a traumatic or severely stressful event that precipitates illness.Reference Howlett and Stein1 The pathogenesis of TSRDs is multifaceted, involving a complex interplay of neurobiological, psychological, behavioural, endocrine and immunogenic disruptions. The primary treatment for TSRDs is psychotherapy, including cognitive–behavioural therapy, cognitive processing therapy, prolonged exposure therapy and eye movement desensitisation and reprocessing.Reference Davis, Zachry and Berke2 Although many individuals who undergo psychotherapy treatments show improvements, drop-out rates are high, and many still maintain their diagnosis following treatment.Reference Lewis, Roberts, Gibson and Bisson3 Physical interventions, such as deep brainReference Khitha and Tayade4,Reference Meeres and Hariz5 and transcranial magneticReference Petrosino, Cosmo, Berlow, Zandvakili, van’t Wout-Frank and Philip6,Reference Kan, Zhang, Zhang and Kranz7 stimulation, have also shown promise for the treatment of TRSDs.Reference Hall, Hoerster and Yancy8 However, it remains unclear whether attrition is as problematic as in psychotherapy. Vagal nerve stimulation (VNS) has recently emerged as an additional potential therapeutic strategy for the treatment of TSRDs.Reference Lamb, Porges, Lewis and Williamson9,Reference Bremner, Gurel, Wittbrodt, Shandhi, Rapaport and Nye10

First approved for the treatment of seizures in palliative care,Reference Yang and Phi11 the use of VNS offers therapeutic relief from various illnesses, with meta-analytic evidence for its efficacy for the treatment of migraine-related pain,Reference Lai, Huang, Huang, Chen and Chen12 drug-resistant epilepsyReference Mao, Chen, Ge, Ye and Cheng13 and treatment-resistant depression.Reference Wu, Liu, Fu, Chen, Cui and Lu14 Modalities of VNS have traditionally been invasive, requiring the implantation of an electrode around the left vagus nerve and a combined battery and pulse generator below the clavicle. Although placement required general anaesthesia, it was considered a risky surgical procedure given the location of the electrode near the carotid artery.Reference Yap, Keatch, Lambert, Woods, Stoddart and Kameneva15 Recent technological advances have enabled the development of transcutaneous VNS (tcVNS), which delivers targeted electrical impulses via a non-invasive electrode array positioned at the cervical or auricular branch of the vagus nerve.Reference Barbella, Cocco, Freri, Marotta, Visani and Franceschetti16,Reference Wang, Li, Wang, Wu, He and Zhang17 This approach circumvents the surgical risks associated with traditional VNS while maintaining therapeutic neuromodulatory capabilities through precisely calibrated electrical parameters. The portable nature of tcVNS devices permits patient-administered treatment in ambulatory settings, representing a significant advancement in therapeutic neuromodulation accessibility.Reference Kim, Marduy, de Melo, Gianlorenco, Kim and Choi18

Most research on the development and persistence of TSRDs has focused on post-traumatic stress disorder (PTSD). Studies of the pathophysiology and neuroimmune-endocrine axis have chiefly been completed on PTSD, and have provided insight into the complex impact these disorders have on the autonomic nervous system (ANS) and its influence on circulating levels of interleukin-6, interleukin-1β, tumour necrosis factor-α, interferon-γ,Reference Passos, Vasconcelos-Moreno, Costa, Kunz, Brietzke and Quevedo19 cortisolReference Pan, Wang, Wu, Wen and Liu20,Reference Morris, Compas and Garber21 and cardiovascular signalling molecules such as norepinephrine.Reference Hendrickson, Raskind, Millard, Sikkema, Terry and Pagulayan22 Studies have reported associations between ANS abnormalities and evidence of decreased heart rate variability (HRV) compared with controls, as well as general ANS dysfunction.Reference Campbell, Wisco, Silvia and Gay23,Reference Schneider and Schwerdtfeger24 Specifically, abnormalities in high-frequency HRV components have been observed in individuals with PTSD, indicating compromised parasympathetic nervous system (PNS) function, which plays a critical role in stress response and emotional regulation. Considering the role of the vagus nerve in orchestrating parasympathetic activity, tcVNS could therefore represent a viable option for people with trauma- and stress-induced psychiatric illnesses.

The involvement of the PNS and sympathetic nervous system (SNS) branches of the ANS within the induction (i.e. the initial physiological response to trauma) and prognosis of PTSD has been well-characterised within the literature.Reference Bedi and Arora25–Reference Vedantham, Brunet, Neylan, Weiss and Mannar27 Moreover, functional deficits common to PTSD – altered arousal, reactivity, intrusive thoughts, negative changes in mood and cognition, and extreme social withdrawal – are linked to physiological experiences, such as autonomic arousal.Reference Tan, Dao, Farmer, Sutherland and Gevirtz28 Furthermore, context has been suggested to play a role; for instance, changes in physiological response (e.g. skin conductance, heart rate) are known to increase in magnitude in the presence of perceived threat, with people with PTSD showing higher physiological responses than healthy controls.Reference Morris, Compas and Garber21,Reference Klaassens, Giltay, Cuijpers, van Veen and Zitman29,Reference Pole30 Indeed, both SNS and PNS systems are known to modulate stressReference Mulkey and du Plessis31 and trauma responses, and alterations in their activity within the context of PTSD result in greater symptom severity.Reference Morris and Rao32 In addition to changes in ANS functioning, disruptions in the negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis are a consistent abnormality observed in individuals with PTSD.Reference Mehta and Binder33 During the heightened stress response, increased concentrations of norepinephrine and epinephrine lead to the release of cortisol, initially amplifying the SNS response and then diminishing it by negative feedback mechanisms.Reference Morris and Rao32 Altered profiles of inflammatory biomarkers in individuals with PTSD are further robustly linked to ANS alterations,Reference Kim, Lee and Yoon34,Reference Katrinli, Oliveira, Felger, Michopoulos and Smith35 with pro-inflammatory markers demonstrated to be linked to PTSD severity.Reference Fonkoue, Marvar, Norrholm, Li, Kankam and Jones36 In patients with PTSD, diminished PNS activity – crucial for modulating heart rate under quiescent states and exerting a tonic inhibitory effect on cardiac function – indicates an impaired ability for physiological regulation and recovery.Reference Agorastos, Kellner, Baker, Stiedl, Martin, Preedy and Patel37,Reference Smith, Deits-Lebehn, Caska-Wallace, Renshaw and Uchino38 This PNS dysregulation underscores an autonomic imbalance that contributes to the pathophysiology of PTSD. tcVNS, by directly enhancing parasympathetic output, presents a novel and targeted approach to rectify this imbalance. The therapeutic promise of tcVNS, predicated on its capacity to restore parasympathetic function, warrants further investigation as a potential intervention for the autonomic dysregulation characteristic of PTSD.

Notably, two theories provide a framework for the potential benefits of tcVNS. Founded on assumptions of phylogenetic heritage,Reference Porges39 the polyvagal theory posits that PNS activity is susceptible to cues of threats, with its activity maintained by perceptions of safety.Reference Kolacz, Kovacic and Porges40 Within this theoretical framework, experiences that promote vagal tone result in improved PTSD symptom experiences. Similarly, the neurovisceral integration theory (NVIT) posits that cardiac vagal tone reflects emotional and cognitive experiences, influencing stimuli processing and attentional processes.Reference Thayer and Lane41,Reference Thayer, Hansen, Saus-Rose and Johnsen42 According to NVIT, imbalances in the integration of autonomic responses with central neural activities may contribute to the cognitive and emotional regulation challenges observed in TSRDs such as PTSD, providing a theoretical basis for understanding these dysfunctions.Reference Gillie and Thayer43 Notably, both theories converge on the premise that the activity of the vagal nerve is decreased by traumatic exposure, and that increases in vagal and cardiac modulation result in improved cognitive and emotional outcomes. Recent meta-analysis further provides some degree of support for these theories, demonstrating a small but present association between PTSD symptom severity and respiratory sinus arrhythmia (RSA), a known measure of vagal activity.Reference Campbell, Wisco, Silvia and Gay23 These theories both provide a neurophysiological basis for the interaction between traumatic stress-related physiological changes and the development of TSRDs.Reference Kolacz, Kovacic and Porges40 However, these theories remain tentative with uncertain trial-based evidence for treating people with TSRDs. As both polyvagal theory and NVIT heavily emphasise the vagus nerve’s role in managing stress and trauma,Reference Williamson, Porges, Lamb and Porges26,Reference Gillie and Thayer43 evaluating tcVNS within the context of TSRDs offers a compelling opportunity to test these theories among psychiatric populations. This approach is grounded in the premise that tcVNS’s direct modulation of vagus nerve activity can provide insights into the nerve’s contribution to stress and trauma resilience.

The current systematic review synthesises evidence on trial literature associated with tcVNS interventions for TRSDs, evaluating the effect of tcVNS on psychiatric symptoms, psychological experiences, autonomic and central nervous system response and immunological changes. The aim was to characterise the current state of evidence and inform researchers, physicians and policy makers involved in this method of care. Beyond evaluating efficacy, the findings were further used to evaluate the current applicability of both polyvagal theory and NVIT within the context of PTSD treatment by vagal stimulation.

Method

This systematic review was conducted in accordance with the PRISMA guidelinesReference Moher, Liberati, Tetzlaff, Altman and Group44 and, where possible, the recommendations of the synthesis without meta-analysis in systematic reviews (SWiM).Reference Campbell, McKenzie, Sowden, Katikireddi, Brennan and Ellis45 The PRISMA checklist is available in the Supplementary Material, available at https://doi.org/10.1192/bjo.2025.10057. The SWiM approach included estimations of common effect sizes where applicable, and assessments of study quality and evidence credibility. The protocol was preregistered on Open Science Framework (https://osf.io/qm4jr) on 17 March 2022, and PROSPERO, an international database of prospectively registered systematic review protocols, on 14 April 2022 (CRD: 42022318838).

Search strategy

Medline, Embase, PsycINFO, CINAHL, Web of Science and Cochrane Central databases, trial registries (i.e. ISRCTN, ClinicalTrials.gov and the National Institutes of Health clinical trial registry), preprint servers (i.e. MedRxiv and PsyArXiv) and Google Scholar were searched from inception to 23 December 2023. References from review articles, opinion publications and listed publications associated with trial registries were hand-searched and screened.

A combination of MeSH terms and keywords associated with VNS and TSRDs were used to identify VNS trials inclusive of people living with TSRDs. We imposed no language, setting or study design restrictions during the search. The search strategy was synthesised by one of the authors (T.B.) and was reviewed independently by three senior authors (C.D., S.R. and S.K.). The search strings used for each database are available within Supplementary File 2.

Rayyan softwareReference Ouzzani, Hammady, Fedorowicz and Elmagarmid46 was used for screening procedures and the tracking of reasons for exclusion. Two independent reviewers (T.B. and S.G.) conducted title, abstracts and full-text screening, and any disagreements were resolved by a third author (C.D.). All included studies were further cross-validated for inclusion by a senior author (S.R.). The search was further updated by (S.E.A. and R.A.H.), and similarly, conflicts were resolved by a third independent reviewer (T.B). The initial screening was completed in April 2022, updated in March 2023 and once again on 23 December 2023, with all updates utilising the same search strategy.

Selection criteria

Randomised controlled studies met inclusion criteria if they (a) administered a VNS-based intervention; (b) included adult patients (i.e. ≥18 years of age) diagnosed with TSRD, as defined and operationalised by a diagnostic manual (e.g. the DSM or ICD) and (c) used clinically validated outcomes measures for TSRD and a quantitative assessment of VNS-related response within the context of TSRDs. Examples included the Clinician-Administered PTSD Scales (CAPS) such as the CAPS-IV-TRReference Blake, Weathers, Nagy, Kaloupek, Gusman and Charney47 or the CAPS-5,Reference Weathers, Bovin, Lee, Sloan, Schnurr and Kaloupek48 PTSD Checklist (PCL), RSA, HRV, electrodermal activity (EDA), cardiac pre-ejection period and immunological markers.

Studies were excluded if they (a) did not use VNS as an intervention, (b) reported non-quantitative evaluations of VNS and TRSD-related outcomes, (c) included a non-adult sample or (d) lacked clear indication of the presence of clinical diagnoses of TSRDs.

Data extraction

Two reviewers (S.G. and T.B.) completed data extraction on 30 March 2023. Study authors were further contacted if there were missing data. Key variables extracted from each study included the following: authors, publication date, geographic region, trial type, primary diagnosis, average age, biological sex proportions, study setting, exposure type, VNS modality, type of comparison group, number of participants, attrition and exclusion rates, length of follow-up, treatment outcomes, sample size, mean scores, standard deviations, event or response rates, reported slopes and frequencies associated with adverse effects.

Risk of bias, quality assessments and the Grading of Recommendations Assessment, Development and Evaluation framework

Quality assessments were conducted using Cochrane’s risk-of-bias tool (RoB-2) for randomised trials.Reference Sterne, Savović, Page, Elbers, Blencowe and Boutron49 Two authors (S.E.A. and R.A.H.) independently conducted risk of bias assessments. Discrepancies not resolved between both authors were further evaluated for resolution by a third author (T.B.). We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess the overall credibility of evidence for each outcome.Reference Schünemann, Brożek, Guyatt and Oxman50 The GRADE approach uses several domains to categorise levels of certainty as very low, low, moderate and high. Evidence from randomised controlled trials is initially graded as high, but can then be downgraded to lower levels depending on study limitations (risk of bias), inconsistency, indirectness, imprecision and publication bias. One reviewer (S.K.) graded the overall quality of evidence with the GRADE framework, with decisions checked by a second reviewer (T.B.).

Data analysis

The state of the evidence on tcVNS included heterogeneous outcomes, overlapping samples and differences in reported effects. As such, a narrative approach was utilised for the synthesis of data. Narrative synthesis clustered findings by outcome type. This included respective reporting of the psychiatric symptoms and psychological experiences, ANS and immunological effects associated with tcVNS comparisons against control conditions in which a non-functional VNS device was used (i.e. sham VNS). Although heterogeneity across studies precluded formal meta-analyses, we conducted a directional analysis by tallying the number of studies reporting positive, negative or null effects for each outcome measure, following the SWiM guidelines.Reference Campbell, McKenzie, Sowden, Katikireddi, Brennan and Ellis45

Results

A total of 296 abstracts were identified during our database search of the literature. A supplementary 26 records were identified through other means, such as manual reference searching. Forty-six were selected for full-text screening against study criteria (see Fig. 1). Seven published studiesReference Lamb, Porges, Lewis and Williamson9,Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51–Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52 met the inclusion criteria for this systematic review (see Table 1). Six of these publications were all sibling studies derived from data collected within the same randomised control trial protocol (identifier NCT02992899). All studies focused on PTSD with no reported outcomes relating to other forms of TSRDs.Reference Lamb, Porges, Lewis and Williamson9,Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51–Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52 Risk-of-bias analysis showed low or moderate risk. One study deemed as having a highly probable risk of bias owing to alterations of their analysis plan as a result of low statistical power. The overall risk of bias and the associated subdomain’s for included studies are presented in Fig. 2. Pooling of data was not possible across studies because of methodological differences and heterogeneity of outcomes. As such, findings were presented in narrative form.

Fig. 1 PRISMA flow diagram.Reference Gazi, Sundararaj, Harrison, Gurel, Wittbrodt and Alkhalaf53 *Includes records identified through Medline, Embase, PsycINFO, CINAHL, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), ISRCTN and ClinicalTrials.gov.

Table 1 Publication data from the registered randomised controlled trial

a. Indicates sibling study.

PTSD, post-traumatic stress disorder; VNS, vagus nerve stimulation; TBI, traumatic brain injury; RSA, respiratory sinus arrhythmia; EDA, electrodermal activity; HRV, heart rate variability; tcVNS, transcutaneous cervical vagus nerve stimulation; CAPS, Clinician-Administered PTSD Scale; PCL-Civilian, Post-traumatic Stress Disorder Checklist – Civilian version; HRSA, Hamilton Rating Scale for Anxiety; HRSD, Hamilton Rating Scale for Depression; CGI, Clinical Global Impression; IL-6, interleukin-6; IFN-γ, interferon-gamma; RMSSD, root mean square of successive differences between adjacent normal (NN) heart-beat intervals; pNN50, percentage of successive NN intervals that differ by more than 50 ms; RSP, respiratory effort signal; 1/PTT, inverse of pulse transit time.

Fig. 2 Risk of bias assessment of included studies.

The sample sizes within the included studies ranged from 20Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 to 46,Reference Gazi, Wittbrodt, Harrison, Sundararaj, Gurel and Nye55 and the average patient age varied from 29 (s.d. = 8)Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51 to 40 (s.d. = 14) years.Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 All studies were conducted in the USA and included 137 patients with a formal PTSD diagnosis. Notably, all designs identified within the literature followed a randomised controlled trial methodology with double-blinding, and four reported being compliant with the CONSORT statement for transparent reporting of randomised controlled trials.Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51,Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52,Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54,Reference Gurel, Wittbrodt, Jung, Shandhi, Driggers and Ladd56 In all studies, tcVNS was compared with sham VNS treatment. One study provided information on clinically relevant measures of PTSD outcomes and their association with tcVNS exposure.Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 All authors were further contacted to confirm that they did not have any unpublished data relating to clinical measures of PTSD, and correspondence suggested that our identified studyReference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 represents the only randomised controlled trial with clinical assessment of PTSD. Two studies reported psychological outcomes.Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52,Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 Outcomes relating to the ANS were included in four studies,Reference Lamb, Porges, Lewis and Williamson9,Reference Gazi, Sundararaj, Harrison, Gurel, Wittbrodt and Alkhalaf53–Reference Gurel, Wittbrodt, Jung, Shandhi, Driggers and Ladd56 and two studies provided data relating to immunological markers.Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51,Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 Out of the seven included randomised controlled trials, six used repeated tcVNS exposure methodology and trauma scripts for stress induction.Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51–Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52

Psychiatric symptoms and central nervous system effects

A single study assessed differences in PTSD symptoms experienced because of tcVNS or sham VNS conditions.Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 Participants were exposed to personalised trauma scripts, derived from their own traumatic experiences, or neutral scripts with emotionally non-arousing content. This dual-script exposure design was instrumental in isolating the specific responses elicited by trauma-relevant versus neutral stimuli. CAPS-5 and PCL measurements demonstrated a decrease in PTSD symptom across the entire sample. However, the results of comparison between active tcVNS and sham group were dependent on the assessment method. A significant decrease of 31% was observed in the tcVNS group when compared with the sham VNS condition, when assessing self-reported PCL reports of PTSD severity. This pattern was further maintained when examining the hyperarousal subscale of the PCL scale. However, no significant difference between the active and sham VNS group was present when comparing outcomes as measured by the CAPS-5. The tcVNS group was further found to experience less somatic anxiety symptoms, as measured by the Hamilton Rating Scale for Anxiety,Reference Maier, Buller, Philipp and Heuser57 when compared with sham VNS exposure. Notably, tcVNS did not significantly differ from sham VNS conditions when evaluating depressive symptoms, as measured by the Hamilton Rating Scale for Depression.Reference Hamilton58 In this study, the use of tcVNS was well-tolerated by participants, with a 16% improvement in treatment drop-out rate in patients with PTSD receiving tcVNS when compared with sham VNS conditions. Following their trial, open-label administration of tcVNS was reported to produce improvement in overall psychiatric symptoms at124 days following study initiation, suggesting a positive therapeutic response to tcVNS in patients with PTSD. In an earlier trial, the same authors observed a reduction in anger responses in patients with PTSD when compared with participants without PTSD during exposure to a personal trauma script, as measured by a visual analogue scale ranging from 0 to 100.Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51 Within the PTSD sample, patients receiving active tcVNS treatment rather than sham VNS stimulation were further found to be associated with a decrease in anger experiences when exposed to a personalised exposure script. No such difference was reported when comparing active and sham VNS conditions within healthy members of their sample.

Another randomised controlled trial provided information on phenomenological differences in distress experienced during exposure to trauma and neutral scripts.Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52 To obtain their sample, trained staff conducted a structured interview following the Structured Clinical Interview for DSM-5 disorders (SCID-5)Reference First, Williams, Karg and Spitzer59 and used the CAPS-5 to determine the presence of PTSD, which was required for inclusion in their study. No difference between active and sham VNS conditions was established in anger, anxiousness, fear and nervousness as determined by the visual analogue ratings of participants. Moreover, no differences in dissociation were observed between the two conditions. Similarly, there was no significant difference in reported psychological distress within their sample when comparing tcVNS and sham VNS conditions across exposure conditions. Despite the lack of difference in these psychological measures, differences in brain imaging as an outcome of receiving tcVNS were identified. Most notable, tcVNS was found to produce greater activity in the anterior cingulate cortex (ACC) and its subdivisions, such as the subgenual, anterior dorsal and posterior dorsal regions. In contrast, sham VNS exposure was associated with decreased ACC activity. In addition to increased insula activity, sham VNS exposure was found to predict greater left frontal, precentral gyrus and thalamus activity when compared with active tcVNS. Moreover, increased hippocampal activity was only observed to be associated with tcVNS exposure. Overall, findings suggest that tcVNS encourages central nervous system changes that, within the context of PTSD, have been associated with improved autonomic control and emotion regulation capacity. Table 2 summarises the results. It was not possible to calculate a common effect size because of the range of outcomes measured.

Table 2 Summary table of results

a. On some measures.

b. One study contained healthy participants as well as people with post-traumatic stress disorder.

Autonomic nervous system

Gurel and colleaguesReference Gurel, Wittbrodt, Jung, Shandhi, Driggers and Ladd56 reported greater parasympathetic activity changes in participants within the tcVNS group compared with sham VNS conditions. Their sample was entirely composed of participants with PTSD, confirmed by SCID and CAPS assessments. Notably, these changes towards parasympathetic dominance were based on tcVNS having significant effects on non-linear HRV (i.e. Poincare-based short-term HRV/Poincare-based short- and long-term HRV; SD1/SD2), photoplethysmogram amplitude and pulse arrival time (PAT) measures. These Poincare-based SD1/SD2 ratios capture short- and long-term fluctuations in heart rhythm and enable distinctions between PNS and SNS inputs, complementing the observed increases in photoplethysmogram amplitude and decreases in PAT that collectively point towards enhanced parasympathetic drive. The increased SD1/SD2 ratio is reflective of more beat-to-beat variability governed by parasympathetic influences, higher photoplethysmogram amplitude indicates parasympathetic-mediated vasodilation and shorter PAT suggests increased parasympathetic modulation of heart rate, collectively demonstrating a shift towards parasympathetic dominance. Concurrently, a decrease in heart rate was further observed. These observations were made within neutral exposure conditions, in which no differences in frequency-based HRV, EDA, respiratory factors, seismocardiography and blood pressure measurements were reported. Findings during traumatic script exposure conditions converged with the aforementioned neutral exposure results. During stress-inducing tasks (e.g. public speaking), participants exposed to tcVNS displayed an increased pre-ejection period (i.e. SNS withdrawal), indicating decreased sympathetic arousal and decreased vascular constriction as measured by pulse pressure, which may reflect an increase PNS activity or convergence towards a decrease in SNS influence. In this context, a lengthening of the pre-ejection period (i.e. the interval from ventricular depolarisation to aortic valve opening) further underscores reduced sympathetic outflow.

Gazi and colleagues expanded upon the work conducted by Gurel et al,Reference Gurel, Wittbrodt, Jung, Shandhi, Driggers and Ladd56 examining parasympathetic activity by using the reciprocal of pulse transit time (1/PTT) because of its greater robustness and decreased influence from variability in assessments of pre-ejection periods.Reference Gazi, Sundararaj, Harrison, Gurel, Wittbrodt and Alkhalaf53 Within their sample of participants diagnosed with PTSD, percentage differences in 1/PTT were significantly different between tcVNS and sham VNS conditions, but only when patients were exposed to a traumatic script. This difference was present during and within the first minute of exposure. Examinations of neutral stimulus exposure and after the first-minute assessments did not differ between active and control conditions. A further study by the same authors reported an increased level of root-mean-square of successive differences (RMSSD) of normal-to-normal intervals and percentage of successive normal-to-normal intervals that differ by more than 50 ms (pNN50) in the tcVNS group when compared with sham VNS conditions when looking at their sample with PTSD.Reference Gazi, Wittbrodt, Harrison, Sundararaj, Gurel and Nye55 Because RMSSD and pNN50 assess short-term beat-to-beat variability, they serve as sensitive indices of vagal tone, consistent with the observed increases under tcVNS. Differences in pNN50 were only observed as present during the first minute of tcVNS, whereas greater RMSSD activity was present during the entire 2min of vagal stimulation. Notably, tcVNS-induced differences from sham VNS were observed to depend on the presence of PTSD. Within their healthy sample, an increase in expiratory time was noted in the tcVNS group post-stimulation when compared with sham VNS. In contrast, HRV rather than respiratory rate was observed to differ during the 2 min of tcVNS stimulation as opposed to post stimulation when compared with sham VNS and active PTSD groups.

A final study evaluated RSA and EDA activity within the context of a startle-blink paradigm and examined HRV at different postural tilting angles.Reference Lamb, Porges, Lewis and Williamson9 However, because of sampling limitations, they pooled their healthy controls with their PTSD group during quantitative analyses. Within their mixed sample (i.e. inclusive of non-PTSD participants), an 0.88 standard deviation increase in parasympathetic activity attributable to tcVNS was detected. RSA, which reflects vagal influence on heart rate across the respiratory cycle, and EDA, a measure of sympathetic-driven skin conductance, both supported this increase in parasympathetic tone. Although these results do not allow extrapolation specific to PTSD, visual inspection of their provided figure of patients living with PTSD and traumatic brain injury displays RSA differences during measurements at 30- and 60-degree postural tilting angles. Table 2 summarises the results. As before, it was not possible to calculate a common effect size because of the range of outcomes measured.

Inflammatory response to VNS

Within their 2021 publication, Bremner and colleagues reported the presence of an increased interleukin-6 concentration in participants within the sham VNS condition when compared with tcVNS conditions. However, it is pivotal to note that this observation was present both before and after administration of tcVNS.Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 In contrast, within their 2020 trial, Bremner and colleagues identified an increase in interleukin-6 and interferon-γ following exposure to a personalised trauma script. This inflammatory difference was further demonstrated to be greater in patients with PTSD when compared with the immune response of healthy controls. Notably, tcVNS was determined to block the expected increased levels of interleukin-6 and interferon-γ when compared with sham VNS conditions.Reference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51 No differences were observed in interleukin-2, interleukin-1β and tumour necrosis factor-α.

GRADE assessments

Table 3 presents the GRADE assessments for the eight outcomes of interest. Entries for risk of bias and inconsistency were derived from Fig. 2. In terms of indirectness, all studies were rated as having serious limitations largely because of concerns about whether the population and/or intervention differed from those that might be relevant for the wider population. All outcomes were rated as having severe limitations under imprecision, because data came from one or two small studies.

Table 3 GRADE ratings for evidence certainty

Given the impossibility to test for publication bias by using tests of funnel asymmetry, this was assessed in terms of the number and size of studies, or possible conflicts of interest in study sponsors. Despite there being relatively few unpublished studies, all outcomes were rated as being at moderate risk of publication bias because of the limited number of small studies. Notably, five out of the seven studiesReference Bremner, Gurel, Jiao, Wittbrodt, Levantsevych and Huang51,Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54,Reference Gazi, Wittbrodt, Harrison, Sundararaj, Gurel and Nye55–Reference Wittbrodt, Gurel, Nye, Shandhi, Gazi and Shah52 reported either having an author that received funding from a device manufacturer or having obtained the devices for their study by the manufacturer free of charge. However, no evidence was available to assess whether these disclosures influenced the findings reported in the studies.

Discussion

To our knowledge, the present systematic review represents the first evidence synthesis on tcVNS interventions for TSRDs. However, all papers identified were focused on PTSD, demonstrating a lack of any identifiable data point describing tcVNS use in non-PTSD forms of TSRDs. Although we searched databases from inception to present, publication dates ranged from 2017 and 2022, confirming the novelty of VNS research within the field of biological psychology and psychiatry. Although all seven identified papers used a robust methodology in which randomisation and blinding were present, only one study was interventional in a clinically relevant way reporting PTSD symptom outcomes. Therefore, the overall quality of evidence for the treatment of PTSD with tcVNS is very low. Moreover, the limited number of small studies and moderate overall risk of bias meant that the certainty of the overall evidence was also very low. Moreover, six out of the seven publications on the topic are all derived from the same data collection effort. Thus, findings are not yet replicated enough to entail applicability to the patient population. In addition, despite our comprehensive database search without geographical restrictions, all identified studies were conducted in the USA, limiting our understanding of tcVNS efficacy across different healthcare systems and cultural contexts. This geographical homogeneity is particularly significant, given that PTSD manifestation and treatment responses can vary substantially across cultural settingsReference Bernardi, Engelbrecht and Jobson60 and healthcare delivery approaches.Reference Cook, Zeber, Simiola, Rossom, Scherrer and Owen-Smith61 The generalisability of current findings to diverse global populations therefore remains uncertain and in need of multicentre international trials.

Currently, first-line treatment for PTSD involves psychotherapy-based care, such as cognitive–behavioural therapyReference Harvey, Bryant and Tarrier62,Reference Brown, Dewey, Bunnell, Boyd, Wilkerson and Mitchell63 and eye movement desensitisation and reprocessing,Reference Watkins, Sprang and Rothbaum64 and antidepressant medication, including selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors.Reference Ehret65 Despite the availability of effective interventions, not all patients experience recovery.Reference Jonas, Cusack, Forneris, Wilkins, Sonis and Middleton66 We therefore conducted this systematic review to determine the effect of tcVNS in producing sustained change in PTSD outcomes and, more broadly, TSRDs. Contrary to anticipation, the present state of evidence on tcVNS as a treatment intervention for individuals with PTSD was limited and not sufficient for clinical practice, as demonstrated by evidence synthesis. Although all studies focused on clinical samples living with PTSD, evidence of psychiatric symptom response was only present in one randomised controlled trial evaluation.Reference Bremner, Wittbrodt, Gurel, Shandhi, Gazi and Jiao54 Moreover, differences in PTSD symptom experience within the study depended on the symptom measurement type, with non-significant results associated with using CAPS and significant changes only observed in self-reported measurements of PTSD severity (i.e. PCL). Furthermore, no information relating to remission outcomes or the number needed to treat was reported within the literature, suggesting that available evidence relating to VNS for the treatment of PTSD is not currently considering critical clinical measures of treatment efficacy.

Most of the literature examined physiological responses, and most examined the effect of VNS within both neutral and stress exposure conditions. This review provides tentative evidence of autonomic modulation caused by VNS treatment. Notably, evidence synthesis on patients with PTSD reflects similar physiological responses to reports of VNS use in healthy controls.Reference Nonis, D’Ostilio, Schoenen and Magis67 Our systematic review uncovered preliminary evidence demonstrating differences in cerebral activity attributable to direct VNS. Notably, tcVNS induced marked increases in activity within the ACC, including its subgenual, anterior dorsal and posterior dorsal subdivisions, and the left hippocampus, areas critically involved in the processing of emotionsReference Stevens, Kim, Galatzer-Levy, Reddy, Ely and Nemeroff68,Reference Milad, Quirk, Pitman, Orr, Fischl and Rauch69 and memory.Reference Shin, Rauch and Pitman70 These regions have been consistently implicated in the pathophysiology of PTSD, serving as key neural substrates for the disorder’s characteristic symptoms of dysregulated affect and intrusive memories.Reference Thomaes, Dorrepaal, Draijer, de Ruiter, Elzinga and Sjoerds71,Reference Kunimatsu, Yasaka, Akai, Kunimatsu and Abe72 In contrast, sham VNS stimulation failed to specifically target the neural pathways associated with therapeutic benefits observed in the tcVNS group. Thus, our finding lends some support to the NVIT as it suggests the presence of direct influence exerted by vagal nerve alterations and neurocognitive processes. Additionally, observed differences in hippocampal activity may reflect the strong influence associated with tcVNS treatments. Although this was only examined by one randomised controlled trial within the literature, previous evidence has demonstrated decreased hippocampal volumes within individuals with PTSDReference Villarreal, Hamilton, Petropoulos, Driscoll, Rowland and Griego73 and a diminished volume that plays a role in PTSD-related processes such as avoidance-based and extinction learning, avoidance symptoms,Reference Sripada, Garfinkel and Liberzon74,Reference Sehlmeyer, Schöning, Zwitserlood, Pfleiderer, Kircher and Arolt75 emotional memory formation, consolidation and retrieval.Reference Schwabe, Nader and Pruessner76 Considering the presence of dysregulation in HPA negative feedback within PTSD and the role of the hippocampus in both modulating and attenuating HPA activity during chronic stress experiences,Reference Zhu, Liu, Li, Liu, Chen and Han77 current evidence warrants further replication and extension examining temporal precedence in which tcVNS-induced alterations of hippocampal activity may further promote the enhanced HPA control. In the broader literature, evidence of marked systemic inflammation in patients with PTSD is robust, and its outcomes are related to multisystemic illness development, such as in the case of cardiovascular and digestive diseases.Reference Brudey, Park, Wiaderkiewicz, Kobayashi, Mellman and Marvar78 Within our synthesis, evidence on pro-inflammatory response was non-significant. However, literature pertaining to IL-6 expression provided mixed findings. As such, future examination of specific subtypes of immune messengers is of great value.

The current evidence provides preliminary experimental validation that serves as an initial proof of concept for the premise that VNS may alter specific aspects associated with PTSD phenomenology, rather than the totality of PTSD-related morbidity. This is reflected in the overall certainty of evidence being rated as very low, using the GRADE framework. Future studies should evaluate tcVNS as an adjunct to first-line interventions. This approach would enable assessment of both multimodal efficacy and treatment response times. Particular attention should focus on how tcVNS may facilitate the resolution of specific symptoms, notably hyperarousal, during standard therapeutic protocols. Furthermore, the current evidence suggests that timing may be necessary when considering this therapeutic modality. For instance, Gazi et alReference Gazi, Sundararaj, Harrison, Gurel, Wittbrodt and Alkhalaf53 reported acute effects within 2 min of exposure, and evidence suggests tcVNS as potentially reducing symptomatic experience during stress induction,Reference Gurel, Wittbrodt, Jung, Shandhi, Driggers and Ladd56 rather than providing overall relief of PTSD-related experiences. Future evidence should consider increasing methodological homogeneity to the extent that meta-analysis becomes possible; with the inclusion of PTSD-related symptom experience, the evidence generated could provide greater clarity on the role of tcVNS as a potential intervention for clinicians. Notably, most evaluations of autonomic activity resulting from tcVNS application were transient. There remains a need to explore the long-term effects of tcVNS on the ANS, particularly by comparing outcomes of repeated booster administrations with those of single-day usage. We also recommend that studies examining tcVNS within the context of psychiatric illness emphasise symptom outcome-related data collection and analysis, even if done as a secondary outcome; thus generating much-needed evidence on its efficacy for further meta-analytical evaluation of its potential benefits to patient populations. Similarly, considering the state of evidence and the portability of tcVNS devices, clinical trials should evaluate its potential in acute event management. Overall, data on symptomatic outcomes during exposure to stress inductive stimuli remains dire. Upon thorough examination of the evidence, which is limited to findings from two small-scale studies, it becomes apparent that the contemporary clinical scientific literature is devoid of sufficient empirical support for the theoretical claims suggesting that tcVNS exerts a direct effect on the symptoms of PTSD. This lack of evidence shows that we cannot promote these theories as clinically relevant for treatment at this time.

Clinical implications

From the vantage point of practising psychiatrists and psychotherapists, these findings underscore both the promise and the practical hurdles of adopting tcVNS. Although standard treatments such as psychotherapy and appropriate pharmacotherapies remain the bedrock of PTSD care, emerging evidence hints that tcVNS might help stabilise hyperarousal symptoms during therapy sessions. In particular, its physiological target may open avenues for patients who have demonstrated limited response to conventional strategies, offering an adjunctive option that could potentially address residual stress reactivity and autonomic dysregulation. However, without robust clinical trials and more consistent methodological approaches, integrating tcVNS into routine practice would be premature. The conceptual alignment of tcVNS with established psychotherapeutic frameworks nonetheless warrants further exploration, as combining neuromodulatory techniques with evidence-based psychotherapy could yield synergistic effects, thereby refining and personalising PTSD interventions.

In conclusion, theories relating to autonomic response may provide a framework for future research on tcVNS and TSRD-related outcomes. Currently, there remains no empirical evaluations of tcVNS within the context of treating non-PTSD forms of TSRDs. Notably, the current literature assessing the role of vagal stimulation in treating PTSD does not meet evidence-based medicine standards, and clinicians should remain wary of its utility in treating patients with TSRDs. Although preliminary evidence does provide an early-stage proof of concept for the induction of PNS dominance as a result of tcVNS exposure, the effects of tcVNS seem to be short-lasting, and the effect of repeated administration on longitudinal outcomes within the ANS remains unknown. The preliminary evidence of autonomic modulation through tcVNS, particularly its effects on hyperarousal and anger responses, represents a potentially novel pathway for therapeutic intervention in trauma-related disorders. However, substantial empirical validation through rigorous clinical trials specifically assessing PTSD prognosis remain essential before any therapeutic applications can be considered.

Supplementary material

The supplementary material is available online at https://doi.org/10.1192/bjo.2025.10057

Author contributions

T.B., S.R., C.D., S.K. and F.E. contributed to the design and conception of the study. T.B., S.G., S.E.A., R.A.H., J.N., S.R. and C.D. were involved in screening the texts for inclusion in the review. S.G. and T.B. extracted the data. S.R., T.B., M.A.P.-B., S.K. and C.D. led the manuscript’s write-up. S.R. and T.B. contributed to the analysis and interpretation of the synthesis. All other authors provided a critical review of the manuscript and assisted with revising the manuscript. T.B. coordinated, and S.R. and C.D. supervised the systematic review. All authors approved the final manuscript for submission. T.B. and S.R. affirm that the manuscript is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted and any discrepancies from the study as planned within our registered PROSPERO protocol (CRD: 42022318838) have been explained.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

S.K. is an editorial board member for BJPsych Open. All other authors have no competing interests to declare.

References

Howlett, JR, Stein, MB. Prevention of trauma and stressor-related disorders: a review. Neuropsychopharmacology 2016; 41: 357–69.10.1038/npp.2015.261CrossRefGoogle ScholarPubMed
Davis, AA, Zachry, CE, Berke, DS. Physical interventions for the treatment of trauma and stressor-related disorders: a comprehensive systematic review. Ment Health Phys Act 2021; 20: 100401.10.1016/j.mhpa.2021.100401CrossRefGoogle Scholar
Lewis, C, Roberts, NP, Gibson, S, Bisson, JI. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur J Psychotraumatol 2020; 11: 1709709.10.1080/20008198.2019.1709709CrossRefGoogle ScholarPubMed
Khitha, V, Tayade, S. Application of deep brain stimulation in refractory post-traumatic stress disorder. Cureus 2023; 15: e33780.Google ScholarPubMed
Meeres, J, Hariz, M. Deep brain stimulation for post-traumatic stress disorder: a review of the experimental and clinical literature. Stereot Funct Neurosurg 2022; 100: 143–55.10.1159/000521130CrossRefGoogle ScholarPubMed
Petrosino, NJ, Cosmo, C, Berlow, YA, Zandvakili, A, van’t Wout-Frank, M, Philip, NS. Transcranial magnetic stimulation for post-traumatic stress disorder. Therap Adv Psychopharmacol 2021; 11: 20451253211049921.10.1177/20451253211049921CrossRefGoogle ScholarPubMed
Kan, RL, Zhang, BB, Zhang, JJ, Kranz, GS. Non-invasive brain stimulation for posttraumatic stress disorder: a systematic review and meta-analysis. Transl Psychiatry 2020; 10: 168.10.1038/s41398-020-0851-5CrossRefGoogle ScholarPubMed
Hall, KS, Hoerster, KD, Yancy, WS Jr. Post-traumatic stress disorder, physical activity, and eating behaviors. Epidemiol Rev 2015; 37: 103–15.10.1093/epirev/mxu011CrossRefGoogle ScholarPubMed
Lamb, DG, Porges, EC, Lewis, GF, Williamson, JB. Non-invasive vagal nerve stimulation effects on hyperarousal and autonomic state in patients with posttraumatic stress disorder and history of mild traumatic brain injury: preliminary evidence. Front Med 2017; 4: 124.10.3389/fmed.2017.00124CrossRefGoogle Scholar
Bremner, JD, Gurel, NZ, Wittbrodt, MT, Shandhi, MH, Rapaport, MH, Nye, JA, et al. Application of noninvasive vagal nerve stimulation to stress-related psychiatric disorders. J Personal Med 2020; 10: 119.10.3390/jpm10030119CrossRefGoogle ScholarPubMed
Yang, J, Phi, JH. The present and future of vagus nerve stimulation. J Korean Neurosurg Soc 2019; 62: 344–52.10.3340/jkns.2019.0037CrossRefGoogle ScholarPubMed
Lai, Y-H, Huang, Y-C, Huang, L-T, Chen, R-M, Chen, C. Cervical noninvasive vagus nerve stimulation for migraine and cluster headache: a systematic review and meta-analysis. Neuromodul Technol Neural Interf 2020; 23: 721–31.10.1111/ner.13122CrossRefGoogle ScholarPubMed
Mao, H, Chen, Y, Ge, Q, Ye, L, Cheng, H. Short-and long-term response of vagus nerve stimulation therapy in drug-resistant epilepsy: a systematic review and meta-analysis. Neuromodul Technol Neural Interf 2022; 25: 327–42.10.1111/ner.13509CrossRefGoogle ScholarPubMed
Wu, C, Liu, P, Fu, H, Chen, W, Cui, S, Lu, L, et al. Transcutaneous auricular vagus nerve stimulation in treating major depressive disorder: a systematic review and meta-analysis. Medicine 2018; 97: 97.10.1097/MD.0000000000013845CrossRefGoogle ScholarPubMed
Yap, JY, Keatch, C, Lambert, E, Woods, W, Stoddart, PR, Kameneva, T. Critical review of transcutaneous vagus nerve stimulation: challenges for translation to clinical practice. Front Neurosci 2020; 14: 284.10.3389/fnins.2020.00284CrossRefGoogle ScholarPubMed
Barbella, G, Cocco, I, Freri, E, Marotta, G, Visani, E, Franceschetti, S, et al. Transcutaneous vagal nerve stimulatio (t-VNS): an adjunctive treatment option for refractory epilepsy. Seizure 2018; 60: 115–9.10.1016/j.seizure.2018.06.016CrossRefGoogle ScholarPubMed
Wang, Y, Li, S-Y, Wang, D, Wu, M-Z, He, J-K, Zhang, J-L, et al. Transcutaneous auricular vagus nerve stimulation: from concept to application. Neurosci Bull 2021; 37: 853–62.10.1007/s12264-020-00619-yCrossRefGoogle ScholarPubMed
Kim, AY, Marduy, A, de Melo, PS, Gianlorenco, AC, Kim, CK, Choi, H, et al. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. Sci Rep 2022; 12: 22055.10.1038/s41598-022-25864-1CrossRefGoogle ScholarPubMed
Passos, IC, Vasconcelos-Moreno, MP, Costa, LG, Kunz, M, Brietzke, E, Quevedo, J, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2015; 2: 1002–12.10.1016/S2215-0366(15)00309-0CrossRefGoogle ScholarPubMed
Pan, X, Wang, Z, Wu, X, Wen, SW, Liu, A. Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis. BMC Psychiatry 2018; 18: 1–10.10.1186/s12888-018-1910-9CrossRefGoogle ScholarPubMed
Morris, MC, Compas, BE, Garber, J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev 2012; 32: 301–15.10.1016/j.cpr.2012.02.002CrossRefGoogle ScholarPubMed
Hendrickson, RC, Raskind, MA, Millard, SP, Sikkema, C, Terry, GE, Pagulayan, KF, et al. Evidence for altered brain reactivity to norepinephrine in veterans with a history of traumatic stress. Neurobiol Stress 2018; 8: 103–11.10.1016/j.ynstr.2018.03.001CrossRefGoogle ScholarPubMed
Campbell, AA, Wisco, BE, Silvia, PJ, Gay, NG. Resting respiratory sinus arrhythmia and posttraumatic stress disorder: a meta-analysis. Biol Psychol 2019; 144: 125–35.10.1016/j.biopsycho.2019.02.005CrossRefGoogle ScholarPubMed
Schneider, M, Schwerdtfeger, A. Autonomic dysfunction in posttraumatic stress disorder indexed by heart rate variability: a meta-analysis. Psychol Med 2020; 50: 1937–48.10.1017/S003329172000207XCrossRefGoogle ScholarPubMed
Bedi, US, Arora, R. Cardiovascular manifestations of posttraumatic stress disorder. J Natl Med Assoc 2007; 99: 642–9.Google ScholarPubMed
Williamson, JB, Porges, EC, Lamb, DG, Porges, SW. Maladaptive autonomic regulation in PTSD accelerates physiological aging. Front Psychol 2015; 5: 1571.10.3389/fpsyg.2014.01571CrossRefGoogle ScholarPubMed
Vedantham, K, Brunet, A, Neylan, TC, Weiss, DS, Mannar, CR. Neurobiological findings in posttraumatic stress disorder: a review. Dialogues Clin Neurosci 2000; 2: 23–9.10.31887/DCNS.2000.2.1/kvedanthamCrossRefGoogle Scholar
Tan, G, Dao, TK, Farmer, L, Sutherland, RJ, Gevirtz, R. Heart rate variability (HRV) and posttraumatic stress disorder (PTSD): a pilot study. Appl Psychophys Biof 2011; 36: 27–35.10.1007/s10484-010-9141-yCrossRefGoogle ScholarPubMed
Klaassens, ER, Giltay, EJ, Cuijpers, P, van Veen, T, Zitman, FG. Adulthood trauma and HPA-axis functioning in healthy subjects and PTSD patients: a meta-analysis. Psychoneuroendocrinology 2012; 37: 317–31.10.1016/j.psyneuen.2011.07.003CrossRefGoogle ScholarPubMed
Pole, N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull 2007; 133: 725–46.10.1037/0033-2909.133.5.725CrossRefGoogle ScholarPubMed
Mulkey, SB, du Plessis, AJ. Autonomic nervous system development and its impact on neuropsychiatric outcome. Pediatr Res 2019; 85: 120–6.10.1038/s41390-018-0155-0CrossRefGoogle ScholarPubMed
Morris, MC, Rao, U. Psychobiology of PTSD in the acute aftermath of trauma: integrating research on coping, HPA function and sympathetic nervous system activity. Asian J Psychiatry 2013; 6: 3–21.10.1016/j.ajp.2012.07.012CrossRefGoogle ScholarPubMed
Mehta, D, Binder, EB. Gene× environment vulnerability factors for PTSD: the HPA-axis. Neuropharmacology 2012; 62: 654–62.10.1016/j.neuropharm.2011.03.009CrossRefGoogle ScholarPubMed
Kim, TD, Lee, S, Yoon, S. Inflammation in post-traumatic stress disorder (PTSD): a review of potential correlates of PTSD with a neurological perspective. Antioxidants 2020; 9: 107.10.3390/antiox9020107CrossRefGoogle ScholarPubMed
Katrinli, S, Oliveira, NC, Felger, JC, Michopoulos, V, Smith, AK. The role of the immune system in posttraumatic stress disorder. Transl Psychiatry 2022; 12: 313.10.1038/s41398-022-02094-7CrossRefGoogle ScholarPubMed
Fonkoue, IT, Marvar, PJ, Norrholm, S, Li, Y, Kankam, ML, Jones, TN, et al. Symptom severity impacts sympathetic dysregulation and inflammation in post-traumatic stress disorder (PTSD). Brain Behav Immun 2020; 83: 260–9.10.1016/j.bbi.2019.10.021CrossRefGoogle ScholarPubMed
Agorastos, A, Kellner, M, Baker, D, Stiedl, O. Diminished vagal and/or increased sympathetic activity in post-traumatic stress disorder. In Comprehensive Guide to Post-traumatic Stress Disorder (eds Martin, CR, Preedy, VR, Patel, VB): 1277–95. Springer, 2016.10.1007/978-3-319-08359-9_30CrossRefGoogle Scholar
Smith, TW, Deits-Lebehn, C, Caska-Wallace, CM, Renshaw, KD, Uchino, BN. Resting high frequency heart rate variability and PTSD symptomatology in veterans: effects of respiration, role in elevated heart rate, and extension to spouses. Biol Psychol 2020; 154: 107928.10.1016/j.biopsycho.2020.107928CrossRefGoogle ScholarPubMed
Porges, SW. Orienting in a defensive world: mammalian modifications of our evolutionary heritage. A polyvagal theory. Psychophysiology 1995; 32: 301–18.10.1111/j.1469-8986.1995.tb01213.xCrossRefGoogle Scholar
Kolacz, J, Kovacic, KK, Porges, SW. Traumatic stress and the autonomic brain-gut connection in development: polyvagal theory as an integrative framework for psychosocial and gastrointestinal pathology. Dev Psychobiol 2019; 61: 796–809.10.1002/dev.21852CrossRefGoogle Scholar
Thayer, JF, Lane, RD. A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord 2000; 61: 201–16.10.1016/S0165-0327(00)00338-4CrossRefGoogle Scholar
Thayer, JF, Hansen, AL, Saus-Rose, E, Johnsen, BH. Heart rate variability, prefrontal neural function, and cognitive performance: the neurovisceral integration perspective on self-regulation, adaptation, and health. Ann Behav Med 2009; 37: 141–53.10.1007/s12160-009-9101-zCrossRefGoogle ScholarPubMed
Gillie, BL, Thayer, JF. Individual differences in resting heart rate variability and cognitive control in posttraumatic stress disorder. Front Psychol 2014; 5: 758.10.3389/fpsyg.2014.00758CrossRefGoogle ScholarPubMed
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group, . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–9.10.7326/0003-4819-151-4-200908180-00135CrossRefGoogle ScholarPubMed
Campbell, M, McKenzie, JE, Sowden, A, Katikireddi, SV, Brennan, SE, Ellis, S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020; 368: 16890.Google ScholarPubMed
Ouzzani, M, Hammady, H, Fedorowicz, Z, Elmagarmid, A. Rayyan – a web and mobile app for systematic reviews. Syst Rev 2016; 5: 1–10.10.1186/s13643-016-0384-4CrossRefGoogle Scholar
Blake, DD, Weathers, FW, Nagy, LM, Kaloupek, DG, Gusman, FD, Charney, DS, et al. The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8: 75–90.Google ScholarPubMed
Weathers, FW, Bovin, MJ, Lee, DJ, Sloan, DM, Schnurr, PP, Kaloupek, DG, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assessment 2018; 30: 383–95.10.1037/pas0000486CrossRefGoogle ScholarPubMed
Sterne, JA, Savović, J, Page, MJ, Elbers, RG, Blencowe, NS, Boutron, I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: 14898.Google ScholarPubMed
Schünemann, H, Brożek, J, Guyatt, G, Oxman, A. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. The GRADE Working Group, 2013 (https://gdt.gradepro.org/app/handbook/handbook.html).Google Scholar
Bremner, JD, Gurel, NZ, Jiao, Y, Wittbrodt, MT, Levantsevych, OM, Huang, M, et al. Transcutaneous vagal nerve stimulation blocks stress-induced activation of interleukin-6 and interferon-γ in posttraumatic stress disorder: a double-blind, randomized, sham-controlled trial. Brain Behav Immun Health 2020; 9: 100138.10.1016/j.bbih.2020.100138CrossRefGoogle ScholarPubMed
Wittbrodt, MT, Gurel, NZ, Nye, JA, Shandhi, MMH, Gazi, AH, Shah, AJ, et al. Non-invasive cervical vagal nerve stimulation alters brain activity during traumatic stress in individuals with posttraumatic stress disorder. Psychosom Med 2021; 83: 969–77.10.1097/PSY.0000000000000987CrossRefGoogle Scholar
Gazi, AH, Sundararaj, S, Harrison, AB, Gurel, NZ, Wittbrodt, MT, Alkhalaf, M, et al. Transcutaneous cervical vagus nerve stimulation inhibits the reciprocal of the pulse transit time’s responses to traumatic stress in posttraumatic stress disorder. In 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) (1–5 Nov 2021). IEEE, 2021.10.1109/EMBC46164.2021.9630415CrossRefGoogle Scholar
Bremner, JD, Wittbrodt, MT, Gurel, NZ, Shandhi, MH, Gazi, AH, Jiao, Y, et al. Transcutaneous cervical vagal nerve stimulation in patients with posttraumatic stress disorder (PTSD): a pilot study of effects on PTSD symptoms and Interleukin-6 response to stress. J Affect Disord Rep 2021; 6: 100190.Google ScholarPubMed
Gazi, AH, Wittbrodt, MT, Harrison, AB, Sundararaj, S, Gurel, NZ, Nye, JA, et al. Robust estimation of respiratory variability uncovers correlates of limbic brain activity and transcutaneous cervical vagus nerve stimulation in the context of traumatic stress. IEEE Trans Biomed Eng 2022; 69: 849–59.10.1109/TBME.2021.3108135CrossRefGoogle ScholarPubMed
Gurel, NZ, Wittbrodt, MT, Jung, H, Shandhi, MMH, Driggers, EG, Ladd, SL, et al. Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in posttraumatic stress disorder: a double-blind, randomized, sham controlled trial. Neurobiol Stress 2020; 13: 100264.10.1016/j.ynstr.2020.100264CrossRefGoogle ScholarPubMed
Maier, W, Buller, R, Philipp, M, Heuser, I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988; 14: 61–8.10.1016/0165-0327(88)90072-9CrossRefGoogle ScholarPubMed
Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psycol 1967; 6: 278–96.10.1111/j.2044-8260.1967.tb00530.xCrossRefGoogle ScholarPubMed
First, MB, Williams, JBW, Karg, RS, Spitzer, RL. Structured Clinical Interview for DSM-5 Disorders—Research Version (SCID-5 for DSM-5, Research Version SCID-5-RV, Version 1.0.0). American Psychiatric Association, 2015 (http://www.scid5.org).Google Scholar
Bernardi, J, Engelbrecht, A, Jobson, L. The impact of culture on cognitive appraisals: implications for the development, maintenance, and treatment of posttraumatic stress disorder. Clin Psychol 2019; 23: 91–102.10.1111/cp.12161CrossRefGoogle Scholar
Cook, JM, Zeber, JE, Simiola, V, Rossom, R, Scherrer, JF, Owen-Smith, AA, et al. Comparisons between patients diagnosed with PTSD in primary care versus mental health care in five large civilian health care systems. J Clin Psychol Med Settings 2021; 28: 221–8.10.1007/s10880-020-09706-8CrossRefGoogle ScholarPubMed
Harvey, AG, Bryant, RA, Tarrier, N. Cognitive behaviour therapy for posttraumatic stress disorder. Clin Psychol Rev 2003; 23: 501–22.10.1016/S0272-7358(03)00035-7CrossRefGoogle ScholarPubMed
Brown, WJ, Dewey, D, Bunnell, BE, Boyd, SJ, Wilkerson, AK, Mitchell, MA, et al. A critical review of negative affect and the application of CBT for PTSD. Trauma Violence Abuse 2018; 19: 176–94.10.1177/1524838016650188CrossRefGoogle ScholarPubMed
Watkins, LE, Sprang, KR, Rothbaum, BO. Treating PTSD: a review of evidence-based psychotherapy interventions. Front Behav Neurosci 2018; 12: 258.10.3389/fnbeh.2018.00258CrossRefGoogle ScholarPubMed
Ehret, M. Treatment of posttraumatic stress disorder: focus on pharmacotherapy. Mental Health Clinician 2019; 9: 373–82.10.9740/mhc.2019.11.373CrossRefGoogle ScholarPubMed
Jonas, DE, Cusack, K, Forneris, CA, Wilkins, TM, Sonis, J, Middleton, JC, et al. Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD). Agency for Healthcare Research and Quality, 2013 (https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/ptsd-adult-treatment_research.pdf).10.1037/e553842013-001CrossRefGoogle Scholar
Nonis, R, D’Ostilio, K, Schoenen, J, Magis, D. Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: an electrophysiological study in healthy volunteers. Cephalalgia 2017; 37: 1285–93.10.1177/0333102417717470CrossRefGoogle ScholarPubMed
Stevens, JS, Kim, YJ, Galatzer-Levy, IR, Reddy, R, Ely, TD, Nemeroff, CB, et al. Amygdala reactivity and anterior cingulate habituation predict posttraumatic stress disorder symptom maintenance after acute civilian trauma. Biol Psychiatry 2017; 81: 1023–9.10.1016/j.biopsych.2016.11.015CrossRefGoogle ScholarPubMed
Milad, MR, Quirk, GJ, Pitman, RK, Orr, SP, Fischl, B, Rauch, SL. A role for the human dorsal anterior cingulate cortex in fear expression. Biol Psychiatry 2007; 62: 1191–4.10.1016/j.biopsych.2007.04.032CrossRefGoogle ScholarPubMed
Shin, LM, Rauch, SL, Pitman, RK. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci 2006; 1071: 67–79.10.1196/annals.1364.007CrossRefGoogle ScholarPubMed
Thomaes, K, Dorrepaal, E, Draijer, N, de Ruiter, MB, Elzinga, BM, Sjoerds, Z, et al. Increased anterior cingulate cortex and hippocampus activation in complex PTSD during encoding of negative words. Soc Cogn Affect Neurosci 2013; 8: 190–200.10.1093/scan/nsr084CrossRefGoogle ScholarPubMed
Kunimatsu, A, Yasaka, K, Akai, H, Kunimatsu, N, Abe, O. MRI findings in posttraumatic stress disorder. J Magn Reson Imaging 2020; 52: 380–96.10.1002/jmri.26929CrossRefGoogle ScholarPubMed
Villarreal, G, Hamilton, DA, Petropoulos, H, Driscoll, I, Rowland, LM, Griego, JA, et al. Reduced hippocampal volume and total white matter volume in posttraumatic stress disorder. Biol Psychiatry 2002; 52: 119–25.10.1016/S0006-3223(02)01359-8CrossRefGoogle ScholarPubMed
Sripada, RK, Garfinkel, SN, Liberzon, I. Avoidant symptoms in PTSD predict fear circuit activation during multimodal fear extinction. Front Hum Neurosci 2013; 7: 672.10.3389/fnhum.2013.00672CrossRefGoogle ScholarPubMed
Sehlmeyer, C, Schöning, S, Zwitserlood, P, Pfleiderer, B, Kircher, T, Arolt, V, et al. Human fear conditioning and extinction in neuroimaging: a systematic review. PloS One 2009; 4: e5865.10.1371/journal.pone.0005865CrossRefGoogle ScholarPubMed
Schwabe, L, Nader, K, Pruessner, JC. Reconsolidation of human memory: brain mechanisms and clinical relevance. Biol Psychiatry 2014; 76: 274–80.10.1016/j.biopsych.2014.03.008CrossRefGoogle ScholarPubMed
Zhu, L-J, Liu, M-Y, Li, H, Liu, X, Chen, C, Han, Z, et al. The different roles of glucocorticoids in the hippocampus and hypothalamus in chronic stress-induced HPA axis hyperactivity. PloS One 2014; 9: e97689.10.1371/journal.pone.0097689CrossRefGoogle ScholarPubMed
Brudey, C, Park, J, Wiaderkiewicz, J, Kobayashi, I, Mellman, TA, Marvar, PJ. Autonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular disease. Am J Physiol Regul Integr Compar Physiol 2015; 309: R315–21.10.1152/ajpregu.00343.2014CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1 PRISMA flow diagram.53 *Includes records identified through Medline, Embase, PsycINFO, CINAHL, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), ISRCTN and ClinicalTrials.gov.

Figure 1

Table 1 Publication data from the registered randomised controlled trial

Figure 2

Fig. 2 Risk of bias assessment of included studies.

Figure 3

Table 2 Summary table of results

Figure 4

Table 3 GRADE ratings for evidence certainty

Supplementary material: File

Benzouak et al. supplementary material

Benzouak et al. supplementary material
Download Benzouak et al. supplementary material(File)
File 15.3 KB
Submit a response

eLetters

No eLetters have been published for this article.